Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy

Area of Science:

• Endocrinology
• Bone Metabolism
• Pharmacology

Background:

• Osteoporosis treatment guidelines now include drug holidays, complicating therapy choices.
• Sequencing of anabolic and antiresorptive therapies is a key consideration for physicians.
• Evidence suggests prior antiresorptive use may impact anabolic drug efficacy.

Purpose of the Study:

• To review evidence on optimal sequencing of anabolic and antiresorptive osteoporosis drugs.
• To assess clinical trials supporting initial anabolic therapy followed by antiresorptive agents.
• To explore combination therapy approaches for osteoporosis management.

Main Methods:

• Literature review of current evidence on osteoporosis drug sequencing.
• Analysis of clinical trials evaluating sequential and combination therapies.
• Assessment of impact of prior antiresorptive treatment on anabolic therapy effectiveness.

Main Results:

• Clinical trials increasingly favor initial anabolic therapy followed by antiresorptive agents.
• Prolonged prior antiresorptive treatment may diminish anabolic medication effectiveness.
• Combined denosumab/teriparatide regimens show substantial skeletal benefits.

Conclusions:

• The sequence of osteoporosis drug administration significantly impacts treatment outcomes.
• Initial anabolic therapy followed by antiresorptive agents is a promising strategy.
• Combination antiresorptive/anabolic approaches, like denosumab/teriparatide, offer maximal skeletal benefits.